Atsena Therapeutics has dosed the first patient in its open-label, phase 1/2 LIGHTHOUSE study to evaluate the subretinal ATSN-201 injection for X-linked retinoschisis, according to a company press release.
“Considering the lack of available therapies for X-linked retinoschisis, this is very exciting news for the inherited retinal disease community,” Mark Pennesi, MD, PhD, professor of ophthalmology at Oregon Health & Science University School of Medicine, said in the release.
X-linked retinoschisis (XLRS) is caused by mutations in the RS1 gene, found on the extracellular surface